Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817390 | 0.87 | NR1H4 (0.43) | NR1H4NOTUMGABRB3GABRA2GABRB2 | |
| SCHEMBL1097054 | 0.86 | NR1H4 (0.42) | NR1H4NOTUMALDH1A1NPC1RAB9A | |
| SCHEMBL22392841 | 0.83 | NR1H4 (0.43) | NR1H4NOTUMALDH1A1NPC1RAB9A | |
| SCHEMBL28408582 | 0.80 | NR1H4 (0.47) | NR1H4NOTUMGPBAR1SLC22A12 | |
| SCHEMBL28408579 | 0.79 | NR1H4 (0.47) | NR1H4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20962531 | 0.79 | NR1H4 (0.37) | NR1H4NOTUMGABRB3GABRA2GABRB2 | |
| SCHEMBL20952033 | 0.78 | NR1H4 (0.36) | NR1H4NOTUMALDH1A1NPC1RAB9A | |
| SCHEMBL497962 | 0.76 | GABRB3 (0.47) | NR1H4NOTUMGABRB3GABRA2GABRB2 | |
| SCHEMBL22407512 | 0.76 | NR1H4 (0.41) | NR1H4GPBAR1 | |
| SCHEMBL1095874 | 0.74 | NR1H4 (0.42) | NR1H4NOTUMGABRB2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3704107-B1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3704106-B1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3681881-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| CN-111278817-A | Polycyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885NOTUM 3725/4885GABRB3 887/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | NR1H4 1/4885NOTUM 4784/4885GABRB3 1637/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | NR1H4 1/4885NOTUM 847/4885GABRB3 448/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885NOTUM 585/4885GABRB3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.